DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for conduct disorder — screening already-approved drugs against its 10-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleConduct disorder maps to a 10-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for conduct disorder is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
inositol monophosphatase 1 (IMPA1) — IMPA1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 4-oxidanylphenoxydrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6GIU · 1.39 Å · ligand [1-(4-oxidanylphenoxy)-1-phosphono-ethyl]phosphonic acid (L69). Experimental structure, not a prediction.
What the evidence adds up to
A 1993 review of psychotherapy research for conduct disorder identified several priorities: expanding the criteria used to evaluate outcome, expanding the range of research questions asked about treatment, testing a broader range of treatments and treatment combinations, evaluating long-term treatment effects, and expanding the models to develop and evaluate treatment. The paper discussed the special opportunities a developmental perspective provides for designing treatments for youth of different ages and stages.
A 2014 descriptive analysis of published psychopharmacological randomised controlled trials for children and adolescents with conduct disorder located 15 studies. None of the trials were longer than 10 weeks in length, and none had more than 100 participants. The majority were conducted in inpatient hospital settings with all-male participants. Methodological quality reporting of trials was poor and inconsistent. The authors concluded there is a need to plan and implement future, lengthy conduct disorder medication trials that follow the Consolidated Standards of Reporting Trials guidelines.
A 1989 overview of conduct disorder presented diagnostic criteria, epidemiology, aetiology, and treatment approaches, but provided no new trial data or quantitative results. The review noted that conduct disorder had been revised from four to three categories in the DSM-III-R.
What is still missing are large, long-term, methodologically rigorous trials — particularly for pharmacological interventions — that include female participants, follow standard reporting guidelines, and assess outcomes beyond short-term inpatient settings. No drug has demonstrated efficacy in a definitive trial for conduct disorder.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Development and Psychopathology · 1993 · 271 citations
Treatment of conduct disorder: Progress and directions in psychotherapy research
AbstractAbstract The present paper charts the course for future research on the treatment of conduct disorder. The course builds on current advances both in understanding conduct disorder and its treatment and in the clinical care provided to youth and their families. The paper highlights substantive and methodological advances in contemporary research on both treatment and developmental psychopathology more generally. In light of the current status of treatment research, several priorities are identified, which include expanding the criteria used to evaluate outcome, expanding the range of research questions asked about treatment, testing a broader range of treatments and treatment combinations, evaluating long-term treatment effects, and expanding the models to develop and to evaluate treatment. A plan is presented to guide the progression of research to identify and to develop effective interventions. The special opportunities that a developmental perspective provides for designing treatments for youth of different ages and stages of development are also discussed.
Journal of Evidence-Based Social Work · 2014 · 3 citations
Randomized Controlled Trials of Psychopharmacological Interventions of Children and Adolescents with Conduct Disorder: A Descriptive Analysis
AbstractThis study reviews and assesses published psychopharmaceutical randomized controlled trials targeting youths with the singular diagnosis of conduct disorder. Computerized database searches were completed to identify all randomized controlled trials. Fifteen studies were located and reviewed. Of the 15 studies, none were longer than 10 weeks in length, and none had more than 100 participants. The majority were conducted in inpatient hospital settings, with all-male participants. Methodological quality reporting of trials was poor and inconsistent. Findings indicate that there is a need to plan and implement future, lengthy conduct disorder medication trials that follow the Consolidated Standards of Reporting Trials guidelines. The relevance for social work practice and policy is discussed.
Journal of Child and Adolescent Psychiatric Nursing · 1989 · 2 citations
Conduct Disorder in Childhood and Adolescence: An Update
AbstractConduct disorder is a diagnostic entity that has elicited controversy throughout the years. Classified as a psychiatric disorder of childhood and adolescence, the syndrome of conduct disorder recently was revised from four to three categories in the DSM-III-R (Revised). This article presents an overview of conduct disorders, including diagnostic criteria, epidemiology, etiology, treatment approaches and implications for nursing practice.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
